Engineering hope for adults and children with liver disease.
In a lab on Boulevard Armand-Frappier in Laval, technicians coax human stem cells into something the body recognizes as liver tissue. Down the hall, the same company runs its own discovery, its own manufacturing, its own preclinical work. Most biotechs of this size outsource at least one of those. Morphocell decided to keep all three.
The company is small enough to fit in a single building and ambitious enough to have offices in Boston and Toronto, plans for a subsidiary in Italy, and US$50 million in the bank. Its lead product, ReLiver, is an engineered tissue you implant temporarily into a person whose liver is failing. The tissue does the liver's work for a while, treats the dangerous brain swelling that liver failure causes, and then steps aside as the patient's own organ regenerates. No donor. No lifelong immunosuppression.
That is the pitch in one breath. The longer version starts with a problem that has been stubbornly unsolved for decades.
The liver is one of the few human organs that can regrow. Cut away most of it and, given a few weeks, it grows back. The catch is the few weeks. In acute and acute-on-chronic liver failure, the organ collapses faster than it can recover, and the only definitive fix is a transplant the patient may never get.
Donor organs are scarce, the matching is unforgiving, and a transplant comes attached to a lifetime of immunosuppressant drugs. Supportive care in the ICU buys time, but not enough of it. For children - the patients who first set this company in motion - the options are even thinner.
So the founders asked a slightly heretical question: if the liver can regenerate, what if you didn't need a whole new organ - just a temporary one, made to order, to hold the line while the patient's own liver caught up?
In 2016, Dr. Massimiliano Paganelli - a pediatric transplant hepatologist who also runs the Liver Tissue Engineering and Cell Therapy Laboratory at CHU Sainte-Justine in Montreal - and Dr. Claudia Raggi set out to find a better answer for kids who needed liver transplants and couldn't get them. The Stem Cell Network put in early money, eventually close to a million dollars across the research. In 2018, the work became a company.
The bet was on allogeneic induced pluripotent stem cells - iPSCs. Rather than build a therapy from each patient's own cells (slow, expensive, one batch per person), Morphocell would make engineered tissue from a standard, off-the-shelf cell line, designed to evade the immune system so it wouldn't need to be matched or defended with drugs. It is a harder science problem and a far more scalable product if it works.
Paganelli has led the company as president and CEO since 2019. Raggi serves as chief scientific officer. The pairing of a working transplant doctor and a cell scientist is not an accident - it keeps the science pointed at a clinical problem that one of them has watched up close in a hospital ward.
Drs. Paganelli and Raggi begin research at CHU Sainte-Justine, backed by early Stem Cell Network funding, to find an alternative to liver transplant for children.
The lab's technology spins out into Morphocell Technologies Inc.
Massimiliano Paganelli becomes president and CEO; the platform builds toward iPSC-derived engineered tissue.
First US patent granted by the USPTO for iPSC-derived hepatocyte methods; collaborations with CQDM and Takeda support early research.
Genson Capital leads the initial Series A to advance ReLiver toward first-in-human trials.
A US$10M add-on led by Investissement Quebec and CDP Venture Capital closes the round; an Italian subsidiary is announced.
ReLiver is engineered liver tissue grown from allogeneic iPSCs. In acute and acute-on-chronic liver failure, it is implanted temporarily through a minimally invasive procedure. While it is in place, it does three things: it improves the patient's odds of survival, it treats hepatic encephalopathy - the confusion and coma that come when a failing liver lets toxins reach the brain - and it gives the patient's own liver the breathing room to regenerate.
Because the cells are designed to be immuno-evasive, the goal is to skip immunosuppression entirely. And because the product is made from a standard cell line rather than the patient's own cells, it can be manufactured ahead of time and cryopreserved - an off-the-shelf tissue rather than a bespoke one.
Made from a standard iPSC line, not the patient's own cells - so it can be produced at scale and stored ready to use.
Implanted temporarily. It supports the patient, then steps aside as the native liver regenerates.
Engineered to evade the immune system, aiming to avoid the lifelong drug regimen transplants require.
Caption: An organ you borrow instead of inherit - returned, in a sense, once your own liver gets back on its feet.
Morphocell is still preclinical - it has not run a human trial, and it is careful to say so. What it has accumulated is a string of investors willing to fund the long, expensive road to the clinic, and the operational machinery to walk it. The US$50 million Series A came in two parts: a US$40 million initial close led by Montreal's Genson Capital in early 2024, and a US$10 million add-on in December 2025 led by Investissement Quebec and Italy's CDP Venture Capital. The round stretched the company's runway past three years.
Caption: The rare growth chart where the second, smaller bar is the one that made headlines.
CDP's interest came with a plan attached: Morphocell will set up its first European subsidiary in Italy, using the country's research base and manufacturing infrastructure as a doorway into the European market. Closer to home, Investissement Quebec reinvested, framing the company as a showcase for the province's life-sciences talent.
The stated mission is to transform the treatment of liver disease. The unstated ambition is bigger. The iPSC engineered-tissue platform that produces ReLiver is, in principle, a way to make replacement tissue for other failing organs too - the liver is the first proof, not the last. Early collaborative work with CQDM and the Stem Cell Network has already pointed at adjacent targets like urea cycle disorders.
It is a tidy story, almost suspiciously so: a platform that solves one hard problem and then quietly generalizes. The honest caveat is that none of it has reached a patient yet. Morphocell's job over the next few years is to turn a well-funded thesis into clinical proof-of-concept - the moment when "engineered tissue" stops being a phrase in a press release and becomes something a hepatologist can actually use.
Return to that building in Laval. Today the tissue growing in those incubators is a candidate, not a cure. But the whole premise of the place is that scarcity - of donor organs, of matched tissue, of time - is an engineering problem, not a permanent fact of medicine.
If ReLiver works, the waiting list gets shorter, the immunosuppressant pillbox gets smaller, and the question a parent asks at a children's hospital - the question that started all of this in 2016 - gets a different answer. That is still an if. But it is a well-funded, vertically integrated, two-continent if, run by a doctor who has stood at the bedside the technology is meant to serve.